Pharsight

Symbicort patents expiration

SYMBICORT's oppositions filed in EPO
SYMBICORT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7967011

(Pediatric)

ASTRAZENECA Inhalation device
Feb, 2022

(1 year, 7 months ago)

US7759328 ASTRAZENECA Composition for inhalation
Jan, 2023

(8 months ago)

US8575137 ASTRAZENECA Composition for inhalation
Jan, 2023

(8 months ago)

US10166247 ASTRAZENECA Composition for inhalation
Jan, 2023

(8 months ago)

US8143239 ASTRAZENECA Composition for inhalation
Jan, 2023

(8 months ago)

US11311558 ASTRAZENECA Composition for inhalation
Jan, 2023

(8 months ago)

US11311558

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(2 months ago)

US7759328

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(2 months ago)

US8143239

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(2 months ago)

US8575137

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(2 months ago)

US10166247

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(2 months ago)

US8875699 ASTRAZENECA Inhaler cap strap
Nov, 2024

(1 year, 1 month from now)

US8875699

(Pediatric)

ASTRAZENECA Inhaler cap strap
May, 2025

(1 year, 7 months from now)

US7587988 ASTRAZENECA Inhaler device counter
Apr, 2026

(2 years from now)

US7587988

(Pediatric)

ASTRAZENECA Inhaler device counter
Oct, 2026

(3 years from now)

US8387615 ASTRAZENECA Inhaler cap strap
Mar, 2027

(3 years from now)

US8387615

(Pediatric)

ASTRAZENECA Inhaler cap strap
Sep, 2027

(3 years from now)

US8528545 ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage
Oct, 2028

(5 years from now)

US8616196 ASTRAZENECA Inhalation device and a method for assembling said inhalation device
Apr, 2029

(5 years from now)

US8528545

(Pediatric)

ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage
Apr, 2029

(5 years from now)

US8616196

(Pediatric)

ASTRAZENECA Inhalation device and a method for assembling said inhalation device
Oct, 2029

(6 years from now)

Symbicort is owned by Astrazeneca.

Symbicort contains Budesonide; Formoterol Fumarate Dihydrate.

Symbicort has a total of 21 drug patents out of which 11 drug patents have expired.

Expired drug patents of Symbicort are:

  • US7967011*PED
  • US7759328
  • US8575137
  • US10166247
  • US8143239
  • US11311558
  • US11311558*PED
  • US7759328*PED
  • US8143239*PED
  • US8575137*PED
  • US10166247*PED

Symbicort was authorised for market use on 21 July, 2006.

Symbicort is available in aerosol, metered;inhalation dosage forms.

Symbicort can be used as use for reducing exacerbations of chronic obstructive pulmonary disease; use for the treatment of asthma in patients 6 years of age and older; use for maintenance treatment of chronic obstructive pulmonary disease, use for the treatment of asthma in patients 6 years of age and older; use for maintenance treatment of chronic obstructive pulmonary disease; use for reducing exacerbations of chronic obstructive pulmonary disease, use for the treatment of asthma in patients 6 years of age and older; use for reducing exacerbations of chronic obstructive pulmonary disease; use for maintenance treatment of chronic obstructive pulmonary disease, use for reducing exacerbations of chronic obstructive pulmonary disease; use for maintenance treatment of chronic obstructive pulmonary disease; use for the treatment of asthma in patients 6 years of age and older.

The generics of Symbicort are possible to be released after 07 October, 2029.

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient

Market Authorisation Date: 21 July, 2006

Treatment: Use for the treatment of asthma in patients 6 years of age and older; Use for reducing exacerbations of chronic obstructive pulmonary disease; Use for maintenance treatment of chronic obstructive pulm...

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage

SYMBICORT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic